BeyondSpring Inc. (NASDAQ:BYSI) reports 1Q18 Loss Widen


BeyondSpring Inc. (NASDAQ:BYSI) a clinical stage biopharmaceutical company reported net loss for the first quarter of $ 47.4 million or $ 2.66 per share, compared to loss of $ 13.66 million or $ 0.61 per share for the year-ago quarter.

Analysts polled by Thomson Reuters expected BeyondSpring to report loss of $ 0.73 per share.

During the past few months, we have continued to execute on our strategy to establish our lead asset, Plinabulin, as a potentially superior new therapy for the treatment of chemotherapy-induced neutropenia, or CIN, while also advancing our Phase 3 non-small cell lung cancer trial and earlier-stage programs, said Lan Huang, Ph.D., Chairman, CEO of BeyondSpring.

Be the first to comment

Leave a Reply